Cargando…

Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada

BACKGROUND: The objective of this study was to examine Streptococcus pneumoniae isolates collected from a longitudinal surveillance program in order to determine their susceptibility to currently used fluoroquinolones and of the frequency and type of mutations in the quinolone-resistant determining...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Samir N, Melano, Roberto, McGeer, Allison, Green, Karen, Low, Donald E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823643/
https://www.ncbi.nlm.nih.gov/pubmed/20082699
http://dx.doi.org/10.1186/1476-0711-9-3
_version_ 1782177653089894400
author Patel, Samir N
Melano, Roberto
McGeer, Allison
Green, Karen
Low, Donald E
author_facet Patel, Samir N
Melano, Roberto
McGeer, Allison
Green, Karen
Low, Donald E
author_sort Patel, Samir N
collection PubMed
description BACKGROUND: The objective of this study was to examine Streptococcus pneumoniae isolates collected from a longitudinal surveillance program in order to determine their susceptibility to currently used fluoroquinolones and of the frequency and type of mutations in the quinolone-resistant determining regions (QRDRs) of their parC and gyrA genes. METHODS: The Canadian Bacterial Surveillance Network has been collecting clinical isolates of S. pneumoniae from across Canada since 1988. Broth microdilution susceptibility testing was carried out according to the Clinical and Laboratory Standards Institute guidelines. The QRDRs of the parC and gyrA genes were sequenced for all isolates with ciprofloxacin MIC ≥ 4 mg/L, and a large representative sample of isolates (N = 4,243) with MIC ≤ 2 mg/L. RESULTS: A total of 4,798 out of 30,111 isolates collected from 1988, and 1993 to 2007 were studied. Of those isolates that were successfully sequenced, 184 out of 1,032 with mutations in parC only, 11 out of 30 with mutations in gyrA only, and 292 out of 298 with mutations in parC and gyrA were considered resistant to ciprofloxacin (MIC ≥ 4 mg/L). The most common substitutions in the parC were at positions 137 (n = 722), 79 (n = 209), and 83 (n = 56), of which substitutions at positions 79 and 83 were associated with 4-fold increase in MIC to ciprofloxacin, whereas substitutions at position 137 had minimal effect on the ciprofloxacin MIC. A total of 400 out of 622 isolates with Lys-137 parC mutation belonged to serotypes 1, 12, 31, 7A, 9V, 9N and 9L, whereas only 49 out of 3064 isolates with no mutations belonged to these serotypes. Twenty-one out of 30 isolates with substitutions at position 81 of the gyrA gene had an increased MIC to ciprofloxacin. Finally, we found that isolates with mutations in both parC and gyrA were significantly associated with increased MIC to fluoroquinolones. CONCLUSIONS: Not all mutations, most frequently Lys-137, found in the QRDRs of the parC gene of S. pneumoniae is associated with an increased MIC to fluoroquinolones. The high prevalence of Lys-137 appears to be due to its frequent occurrence in common serotypes.
format Text
id pubmed-2823643
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28236432010-02-18 Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada Patel, Samir N Melano, Roberto McGeer, Allison Green, Karen Low, Donald E Ann Clin Microbiol Antimicrob Research BACKGROUND: The objective of this study was to examine Streptococcus pneumoniae isolates collected from a longitudinal surveillance program in order to determine their susceptibility to currently used fluoroquinolones and of the frequency and type of mutations in the quinolone-resistant determining regions (QRDRs) of their parC and gyrA genes. METHODS: The Canadian Bacterial Surveillance Network has been collecting clinical isolates of S. pneumoniae from across Canada since 1988. Broth microdilution susceptibility testing was carried out according to the Clinical and Laboratory Standards Institute guidelines. The QRDRs of the parC and gyrA genes were sequenced for all isolates with ciprofloxacin MIC ≥ 4 mg/L, and a large representative sample of isolates (N = 4,243) with MIC ≤ 2 mg/L. RESULTS: A total of 4,798 out of 30,111 isolates collected from 1988, and 1993 to 2007 were studied. Of those isolates that were successfully sequenced, 184 out of 1,032 with mutations in parC only, 11 out of 30 with mutations in gyrA only, and 292 out of 298 with mutations in parC and gyrA were considered resistant to ciprofloxacin (MIC ≥ 4 mg/L). The most common substitutions in the parC were at positions 137 (n = 722), 79 (n = 209), and 83 (n = 56), of which substitutions at positions 79 and 83 were associated with 4-fold increase in MIC to ciprofloxacin, whereas substitutions at position 137 had minimal effect on the ciprofloxacin MIC. A total of 400 out of 622 isolates with Lys-137 parC mutation belonged to serotypes 1, 12, 31, 7A, 9V, 9N and 9L, whereas only 49 out of 3064 isolates with no mutations belonged to these serotypes. Twenty-one out of 30 isolates with substitutions at position 81 of the gyrA gene had an increased MIC to ciprofloxacin. Finally, we found that isolates with mutations in both parC and gyrA were significantly associated with increased MIC to fluoroquinolones. CONCLUSIONS: Not all mutations, most frequently Lys-137, found in the QRDRs of the parC gene of S. pneumoniae is associated with an increased MIC to fluoroquinolones. The high prevalence of Lys-137 appears to be due to its frequent occurrence in common serotypes. BioMed Central 2010-01-18 /pmc/articles/PMC2823643/ /pubmed/20082699 http://dx.doi.org/10.1186/1476-0711-9-3 Text en Copyright ©2010 Patel et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Patel, Samir N
Melano, Roberto
McGeer, Allison
Green, Karen
Low, Donald E
Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title_full Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title_fullStr Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title_full_unstemmed Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title_short Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
title_sort characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in canada
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823643/
https://www.ncbi.nlm.nih.gov/pubmed/20082699
http://dx.doi.org/10.1186/1476-0711-9-3
work_keys_str_mv AT patelsamirn characterizationofthequinoloneresistantdeterminingregionsinclinicalisolatesofpneumococcicollectedincanada
AT melanoroberto characterizationofthequinoloneresistantdeterminingregionsinclinicalisolatesofpneumococcicollectedincanada
AT mcgeerallison characterizationofthequinoloneresistantdeterminingregionsinclinicalisolatesofpneumococcicollectedincanada
AT greenkaren characterizationofthequinoloneresistantdeterminingregionsinclinicalisolatesofpneumococcicollectedincanada
AT lowdonalde characterizationofthequinoloneresistantdeterminingregionsinclinicalisolatesofpneumococcicollectedincanada